Drugs / Relatilmab
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05629546 Background | Nov 2024 → Feb 2029 expected | metastatic melanoma | Washington University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Relatilmab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05629546 ↗ |